We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Neuroscience has announced the launch of Azilect (rasagiline mesylate), the first and the only once-daily treatment for Parkinson's disease now available by prescription in pharmacies throughout Canada.
German drugmaker Merck KGaA announced today that it has entered into an agreement with the Bertarelli family, which owns the majority stake of Serono, a Geneva-based biotech, to purchase their Serono shares.
Hospira has announced it will acquire Australian generic drugmaker Mayne Pharma. Under the terms of the agreement, Mayne shareholders will receive $4.10 (Australian) in cash per outstanding ordinary share of Mayne, or a total equity consideration of approximately $2.6 billion (Australian), including options.
Health Canada is warning consumers not to use the natural health product Libidus because it contains an undeclared pharmaceutical ingredient, a modified form of vardenafil, which is similar to the active pharmaceutical ingredient found in the prescription drug Levitra.
Protiva Biotherapeutics Inc. announced the intent of the U.S. Defense Threat Reduction Agency to award a US$3.6 million grant to a consortium which includes the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and Protiva.
Bausch & Lomb will make adjustments to its worldwide contact lens manufacturing workforce over the next several months, reducing approximately 400 positions, the majority of them temporary jobs, in manufacturing plants in Europe and the United States.
The Australian Financial Review newspaper, earlier this week, reported that Melbourne-based pharmaceuticals manufacturer Mayne Pharma Ltd. has received an over $1.5 billion takeover approach from an international rival, on Wednesday.
Teva Pharmaceutical Industries Ltd. and Procognia (Israel) Ltd. announced that they had reached a cooperation agreement on two biopharmaceutical products.
Angola has launched a poliovirus vaccine campaign aimed at immunizing more than 3 million children under the age of 5 in the southeastern part of the country.